Nuo Therapeutics Q2 FY26 revenue more than doubles to $1.77 million; gross profit climbs to $1.17 million
AURX•Q2 revenue and gross profit increase
Nuo Therapeutics posted Q2 revenue of USD 1.77 million, more than doubled from a year earlier, driven by Aurix growth.
Gross profit climbed to about USD 1.17 million; gross margin fell 11 percentage points to about 66% on Smith+Nephew transfer pricing.
Six-month revenue grows 163% year over year
Six-month revenue rose to about USD 3.07 million, up 163% year over year; gross margin dropped 10 percentage points to about 66%.
Supply risk and temporary out-of-stock event
Supply risk increased after Pfizer warned TJMI thrombin will be unavailable until early 2027, triggering a temporary Aurix out-of-stock in August.
Operating expenses rise on compensation and commissions
Operating expenses rose to about USD 1.34 million, due to higher compensation and third-party commissions; professional fees declined.
